Differential regulation of Cav3.2 and Cav2.2 calcium channels by CB1 receptors and cannabidiol

Cannabinoids are a promising therapeutic avenue for chronic pain. However, clinical trials often fail to report analgesic efficacy of cannabinoids. Inhibition of voltage gate calcium (Cav) channels is one mechanism through which cannabinoids may produce analgesia. We hypothesized that cannabinoids and cannabinoid receptor agonists target different types of Cav channels through distinct mechanisms.

[1]  J. Crippa,et al.  Cannabidiol enhances the antinociceptive effects of morphine and attenuates opioid-induced tolerance in the chronic constriction injury model , 2022, Behavioural Brain Research.

[2]  Christopher H George,et al.  Planning experiments: Updated guidance on experimental design and analysis and their reporting III , 2022, British journal of pharmacology.

[3]  Erika K. Harding,et al.  Central and peripheral contributions of T-type calcium channels in pain , 2022, Molecular brain.

[4]  M. Glass,et al.  Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (CaV3) Inhibitors. , 2022, ACS chemical neuroscience.

[5]  Xiaoqun Wang,et al.  Structure, gating, and pharmacology of human CaV3.3 channel , 2022, Nature Communications.

[6]  C. Bladen,et al.  Inhibition of human recombinant T‐type calcium channels by phytocannabinoids in vitro , 2022, British journal of pharmacology.

[7]  N. A. Caballero,et al.  Theoretical Study of the Structural Stability, Chemical Reactivity, and Protein Interaction for NMP Compounds as Modulators of the Endocannabinoid System , 2022, Molecules.

[8]  S. Ovchinnikov,et al.  ColabFold: making protein folding accessible to all , 2022, Nature Methods.

[9]  Zhuo Huang,et al.  Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2.2. , 2021, Cell reports.

[10]  Stephen P. H. Alexander,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors , 2021, British journal of pharmacology.

[11]  Adam J Pawson,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels , 2021, British journal of pharmacology.

[12]  L. Dreyer,et al.  Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind placebo-controlled trial. , 2021, Pain.

[13]  Jennifer A. Smith,et al.  Cannabidiol activates neuronal Kv7 channels , 2021, bioRxiv.

[14]  N. Yan,et al.  Structure of human Cav2.2 channel blocked by the painkiller ziconotide , 2021, Nature.

[15]  Y. de Koninck,et al.  Sexual dimorphism in a neuronal mechanism of spinal hyperexcitability across rodent and human models of pathological pain , 2021, bioRxiv.

[16]  Erika K. Harding,et al.  The T‐type calcium channel antagonist, Z944, reduces spinal excitability and pain hypersensitivity , 2021, British journal of pharmacology.

[17]  D. Finn,et al.  Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. , 2021, Pain.

[18]  J. Mlost,et al.  Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action , 2020, International journal of molecular sciences.

[19]  Dennis J Sholler,et al.  Therapeutic Efficacy of Cannabidiol (CBD): a Review of the Evidence From Clinical Trials and Human Laboratory Studies , 2020, Current Addiction Reports.

[20]  Christopher H George,et al.  ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020 , 2020, British journal of pharmacology.

[21]  Ulrich Dirnagl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research* , 2020, BMC Veterinary Research.

[22]  Esther J Pearl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research , 2020, PLoS biology.

[23]  M. Rowbotham,et al.  Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. , 2020, Pain.

[24]  Ying-Xian Pan,et al.  Differential regulation of Cav2.2 channel exon 37 variants by alternatively spliced μ-opioid receptors , 2019, Molecular Brain.

[25]  M. Huestis,et al.  Cannabidiol Adverse Effects and Toxicity. , 2019, Current neuropharmacology.

[26]  T. England,et al.  A systematic review of cannabidiol dosing in clinical populations , 2019, British journal of clinical pharmacology.

[27]  A. Moqrich,et al.  Cav3.2 T-type calcium channels shape electrical firing in mouse Lamina II neurons , 2019, Scientific Reports.

[28]  R. McLaughlin,et al.  Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain , 2018, Pain.

[29]  O. Hogue,et al.  Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort , 2018, The journal of headache and pain.

[30]  Christopher H George,et al.  Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology , 2018, British journal of pharmacology.

[31]  J. McDougall,et al.  Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis , 2017, Pain.

[32]  R. Tallarida,et al.  Single and combined effects of Δ9‐tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy‐induced neuropathic pain , 2017, British journal of pharmacology.

[33]  F. Grotenhermen,et al.  An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies , 2017, Cannabis and cannabinoid research.

[34]  J. Mogil,et al.  Sex differences in neuroimmunity and pain , 2017, Journal of neuroscience research.

[35]  D. Clauw,et al.  Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. , 2016, The journal of pain : official journal of the American Pain Society.

[36]  Gerald W. Zamponi,et al.  Targeting voltage-gated calcium channels in neurological and psychiatric diseases , 2015, Nature Reviews Drug Discovery.

[37]  R. Laprairie,et al.  Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor , 2015, British journal of pharmacology.

[38]  Loren J. Martin,et al.  Different immune cells mediate mechanical pain hypersensitivity in male and female mice , 2015, Nature Neuroscience.

[39]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[40]  A. Moqrich,et al.  The Low-Threshold Calcium Channel Cav3.2 Determines Low-Threshold Mechanoreceptor Function. , 2015, Cell reports.

[41]  T. Pfeifer,et al.  Small organic molecule disruptors of Cav3.2 - USP5 interactions reverse inflammatory and neuropathic pain , 2015, Molecular pain.

[42]  C. Bladen,et al.  Characterization of Novel Cannabinoid Based T-Type Calcium Channel Blockers with Analgesic Effects , 2014, ACS chemical neuroscience.

[43]  G. Toney,et al.  Activation of corticotropin-releasing factor receptors in the rostral ventrolateral medulla is required for glucose-induced sympathoexcitation. , 2014, American journal of physiology. Endocrinology and metabolism.

[44]  M. Lee.  Z944: A first in class T‐type calcium channel modulator for the treatment of pain , 2014, Journal of the peripheral nervous system : JPNS.

[45]  C. Bladen,et al.  The Deubiquitinating Enzyme USP5 Modulates Neuropathic and Inflammatory Pain by Enhancing Cav3.2 Channel Activity , 2014, Neuron.

[46]  S. McAllister,et al.  Cannabidiol inhibits paclitaxel‐induced neuropathic pain through 5‐HT1A receptors without diminishing nervous system function or chemotherapy efficacy , 2014, British journal of pharmacology.

[47]  P. Diaz,et al.  NMP-7 inhibits chronic inflammatory and neuropathic pain via block of Cav3.2 T-type calcium channels and activation of CB2 receptors , 2014, Molecular pain.

[48]  Haitao You,et al.  Analgesic effect of a mixed T-type channel inhibitor/CB2 receptor agonist , 2013, Molecular pain.

[49]  R. W. Turner,et al.  Signaling complexes of voltage-gated calcium channels , 2011, Channels.

[50]  Haitao You,et al.  Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands , 2011, Molecular pain.

[51]  U. Meza,et al.  Protein Kinase C-Mediated Inhibition of Recombinant T-Type CaV3.2 Channels by Neurokinin 1 Receptors , 2010, Molecular Pharmacology.

[52]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[53]  A. Eschalier,et al.  T-Type Calcium Channel Inhibition Underlies the Analgesic Effects of the Endogenous Lipoamino Acids , 2009, The Journal of Neuroscience.

[54]  P. Barrett,et al.  Protein Kinase A Activity Controls the Regulation of T-type CaV3.2 Channels by Gβγ Dimers* , 2009, Journal of Biological Chemistry.

[55]  G. Zamponi,et al.  D2 dopamine receptors interact directly with N-type calcium channels and regulate channel surface expression levels , 2008, Channels.

[56]  M. Connor,et al.  Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol* , 2008, Journal of Biological Chemistry.

[57]  R. Pertwee,et al.  Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond , 2008, Addiction biology.

[58]  T. Soong,et al.  Activation of Corticotropin-Releasing Factor Receptor 1 Selectively Inhibits CaV3.2 T-Type Calcium Channels , 2008, Molecular Pharmacology.

[59]  B. MacVicar,et al.  D1 Receptors Physically Interact with N-Type Calcium Channels to Regulate Channel Distribution and Dendritic Calcium Entry , 2008, Neuron.

[60]  C. Altier,et al.  Signaling complexes of voltage-gated calcium channels and G protein-coupled receptors. , 2008, Journal of receptor and signal transduction research.

[61]  B. Spiegelman,et al.  Direct G Protein Modulation of Cav2 Calcium Channels , 2006, Pharmacological Reviews.

[62]  P. Barrett,et al.  The molecular basis for T-type Ca2+ channel inhibition by G protein β2γ2 subunits , 2006, Proceedings of the National Academy of Sciences.

[63]  A. Molleman,et al.  Cannabinoid signalling. , 2006, Life sciences.

[64]  M. De Waard,et al.  How do G proteins directly control neuronal Ca2+ channel function? , 2005, Trends in pharmacological sciences.

[65]  D. T. Yue,et al.  G Protein-Gated Inhibitory Module of N-Type (CaV2.2) Ca2+ Channels , 2005, Neuron.

[66]  Olivier Poirot,et al.  Silencing of the Cav3.2 T‐type calcium channel gene in sensory neurons demonstrates its major role in nociception , 2005, The EMBO journal.

[67]  H. Adams,et al.  The medicinal use of cannabis in the UK: results of a nationwide survey , 2004, International journal of clinical practice.

[68]  M. Huestis.  Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. , 2005, Handbook of experimental pharmacology.

[69]  L. Petrocellis,et al.  The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.

[70]  Aaron M. Beedle,et al.  Modulation of High Voltage-Activated Calcium Channels by G Protein-Coupled Receptors , 2004 .

[71]  Chien-Chang Chen,et al.  Abnormal Coronary Function in Mice Deficient in α1H T-type Ca2+ Channels , 2003, Science.

[72]  P. Barrett,et al.  T-type calcium channel regulation by specific G-protein βγ subunits , 2003, Nature.

[73]  Chien-Chang Chen,et al.  Abnormal coronary function in mice deficient in alpha1H T-type Ca2+ channels. , 2003, Science.

[74]  Franjo Grotenhermen,et al.  Pharmacokinetics and Pharmacodynamics of Cannabinoids , 2003, Clinical pharmacokinetics.

[75]  P. Lory,et al.  Direct inhibition of T‐type calcium channels by the endogenous cannabinoid anandamide , 2001, The EMBO journal.

[76]  J. Calixto,et al.  Evidence for the participation of kinins in Freund's adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice , 2001, Neuropharmacology.

[77]  D. Ponde,et al.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide , 2001, British journal of pharmacology.

[78]  K. Mackie,et al.  Internalization and Recycling of the CB1 Cannabinoid Receptor , 1999, Journal of neurochemistry.

[79]  K. Mackie,et al.  Distinct Domains of the CB1 Cannabinoid Receptor Mediate Desensitization and Internalization , 1999, The Journal of Neuroscience.

[80]  A. Basbaum,et al.  Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates , 1998, Pain.

[81]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[82]  D S Goodsell,et al.  Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.

[83]  Asmar.  Therapeutic Efficacy , 2020, Definitions.

[84]  K. Mackie,et al.  Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[85]  S. Hunskaar,et al.  Formalin test in mice, a useful technique for evaluating mild analgesics , 1985, Journal of Neuroscience Methods.